Name: Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System (Video) | JoVE Journal
Uploaded: 2025-04-11T12:00:00.000+00:00
Duration: 8 min 15 s
Description: Learn CRISPR-Cas9 gene editing to generate a RIP1 knockout U937 cell line for studying receptor-interacting protein kinase 1 function. This protocol demonstrates precise genetic modification techniques.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This research was funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), grant number NIH 2R15-HL135675-02 to T.J.L.

A schematic representation of the procedure is provided in Figure 1. Guide RNA (gRNA) and the target sequence are given in Table 1. Details of the reagents and the equipment used are listed in the Table of Materials.
1. Harvesting of RIP1 -targeting CRISPR gRNA lentiviral expression vector containing Cas9 endonuclease and puromycin resistance from Escherichia coli
<ol>
	<li>Quadrant-streak E. coli harboring lentiviral vector gRNAonto LB agar plates supplemented with 100 &#181;g/mL Ampicillin.</li>
	<li>Incubate plates at 37&#176;C for 1-2 days until individual colonies are visible in the most dilute area on the plate.</li>
	<li>Select a single colony with a sterile loop and individually add each colony to 5 mL of LB broth supplemented with 100 &#181;g/mL Ampicillin into a 50 mL conical tube. Ensure to pipette thoroughly up and down after adding the single colony to ensure homogenization.</li>
	<li>Vent and tape down the cap of the 50 mL conical tube and incubate in an orbital shaker at 37&#176;C and 225 rpm for 8 h.</li>
	<li>During the 8 h incubation at 37&#176;C, add 40 mL of LB broth supplemented with 100 &#181;g/mL Ampicillin to each of four separate 50 mL conical tubes.</li>
	<li>Following the 8 h incubation at 37&#176;C, take 40 &#181;L of grown E. coli culture and add it to all four 50 mL conical tubes.</li>
	<li>Vent and tape down the caps of the 50 mL conical tubes and incubate them in an orbital shaker at 37&#176;C and 225 rpm for 12-16 h.</li>
	<li>Following this incubation at 37&#176;C, spin down all tubes at 3220 x g in a swinging bucket rotor for 20 min to pellet the grown E. coli bacteria.</li>
	<li>Decant supernatants to a waste beaker, then combine all four pellets in 10 mL of LB broth supplemented with 100 &#181;g/mL Ampicillin.</li>
	<li>Spin down the combined pellets again at max speed in a swinging bucket rotor for 20 min to get a singular pellet.</li>
	<li>Discard as much of the supernatants as possible into the waste beaker, and proceed with one of the following options: (1) Freeze wet pellet as is at -80&#176; for up to 1 month. (2) Proceed with lentiviral vector plasmid purification. 
	NOTE: If option 1 is chosen, the protocol may be paused here.</li>
</ol>
2. Transfection of HEK293T cells with purified CRISPR gRNA lentiviral expression vector targeting RIP1
<ol>
	<li>Seed HEK293T cells overnight at a concentration of 3 &#215; 106 to 5 &#215; 106 cells into a 10 cm plate containing DMEM with 4.5 g/L D-glucose, L-glutamine, 110 mg/L sodium pyruvate, and 10 % heat-inactivated FBS.</li>
	<li>The following day, ensure plates have approximately 70%-90% confluency, then proceed with the protocol.</li>
	<li>Setup the transfection of the cells with a 1:1:1:1 ratio of plasmids (experimental CRISPR plasmid: pLP1: pLP2: pLP/VSVG) using the transfection reagent in a 3:1 ratio (3 parts reagent: 1 part plasmid DNA), along with reduced serum medium. 
	NOTE: The pLP1: pLP2: pLP/VSVG portion of the ratio is a lentiviral packaging mix.
	<ol>
		<li>Equilibrate the transfection reagent, reduced serum medium, CRISPR plasmid DNA, and lentiviral packaging mix to room temperature prior to setup of transfection.</li>
		<li>Mix together 75 &#181;L of the transfection reagent, 2500 &#181;L of reduced serum medium, and 25 &#181;g total DNA (calculation based on spectrophotometer analysis for CRISPR plasmid DNA and 1:1:1:1 ratio with lentiviral packaging mix).</li>
		<li>Allow this mixture to incubate at room temperature for 15-30 min. Carefully pipette the entire volume of this mixture to the confluent HEK293T cell plate right into the media (no need to change media).</li>
	</ol>
	</li>
	<li>Gently swirl the plate to ensure adequate homogenization of the transfection mix and plate media. Incubate the plate at 37 &#176;C for 48 h.</li>
</ol>
3. Lentiviral transduction of U937 cells or target cells
<ol>
	<li>Once the 48-h incubation at 37&#176;C is complete, transfer the media from the producer HEK293T cell plate into a 15 mL conical tube.</li>
	<li>Centrifuge the volume at 800 x g for 5 min at room temperature to pellet any remaining HEK293T cells. Remove all the virus-containing supernatant, taking care not to disturb the pelleted HEK293T cells, and keep it in a separate 15 mL conical tube. Then, decontaminate and discard the pellet-containing tube in the appropriate biohazard waste container. 
	NOTE: HIV-based lentivirus supernatants can be stored at -80&#176;C; however, doing so carries a risk of up to 55% loss of virus stability after the first freeze/thaw cycle19.</li>
	<li>Count and obtain a pellet of 2 &#215; 106 U937 cells in a 15 mL conical tube by centrifuging an appropriate volume at 400 x g for 10 min at room temperature and decant the supernatant, leaving the cell pellet in the tube.</li>
	<li>Resuspend the U937 cell pellet with all the virus-containing supernatant and then centrifuge the tube at 290 x g for 60 min.</li>
	<li>Following centrifugation, use a pipette to resuspend the pellet with the virus-containing supernatant already in the tube.</li>
	<li>Place the tube on an end-over-end rotator (or similar rotating device) for 60 min.
	<ol>
		<li>Following this incubation, centrifuge the tubes at 400 x g for 10 min at room temperature to pellet the cells.</li>
		<li>Resuspend the cell pellet with a 1:1 ratio media mixture of both virus-containing supernatants and complete RPMI-1640 media supplemented with 10% heat-inactivated FBS.</li>
	</ol>
	</li>
	<li>Transfer the cell mixture to a 10 cm tissue culture plate and incubate at 37&#176;C for 48 h.</li>
	<li>Following this incubation, centrifuge the U937 cells at 400 x g for 10 min and remove the supernatant.
	<ol>
		<li>Resuspend the pellet with complete RPMI-1640 media supplemented with 10% heat-inactivated FBS and 5 &#181;g/mL of puromycin and transfer the cells to a T25 flask.</li>
		<li>Incubate cells at 37 &#176;C untouched for 2-3 weeks, ensuring to check on them every 1-2 days for signs of cell growth. 
		NOTE: Once cells become confluent and have a healthy turnover time following an initial passage, they can be tested for the effectiveness of the completed protocol.</li>
	</ol>
	</li>
</ol>
4. Testing effectiveness of the completed protocol in the creation of RIP1 CRISPR mutant cells using Western blot analysis
<ol>
	<li>Generate cellular protein lysates of wild-type (WT) U937 monocytes, non-targeting control (NTC) CRISPR cells, and the RIP1 CRISPR mutant cells11,12,13.</li>
	<li>Run these lysates on an SDS-PAGE gel and proceed with Western blot analysis14.
	<ol>
		<li>Normalize samples to a housekeeping protein first.</li>
		<li>Following normalization, analyze samples for RIP1 protein expression levels to adequately determine the success of creating a RIP1 CRISPR mutant cell line14.</li>
	</ol>
	</li>
	<li>Following western blot analysis conformation, cells can be used for experimentation purposes.</li>
</ol>

<ol><li>Gostimskaya, I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR%E2%80%93Cas9%3A+A+History+of+its+discovery+and+ethical+considerations+of+its+use+in+genome+editing%5BTitle%5D)+AND+%22Biochem+%28Mosc.%29%22%5BJournal%5D)">CRISPR–Cas9: A History of its discovery and ethical considerations of its use in genome editing.</a> Biochem (Mosc.). 87 (8), 777-788 (2022).</li>
<li>Jinek, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+programmable+dual+RNA-guided+DNA+endonuclease+in+adaptive+bacterial+immunity%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">A programmable dual RNA-guided DNA endonuclease in adaptive bacterial immunity.</a> Science. 337 (6096), 816-821 (2012).</li>
<li>Cong, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Multiplex+genome+engineering+using+CRISPR%2FCas+systems%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Multiplex genome engineering using CRISPR/Cas systems.</a> Science. 339 (6121), 819-823 (2013).</li>
<li>Redman, M., King, A., Watson, C., King, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((What+is+CRISPR%2FCas9%5BTitle%5D)+AND+%22Arch+Dis+Child+Educ+Pract+Ed%22%5BJournal%5D)">What is CRISPR/Cas9.</a> Arch Dis Child Educ Pract Ed. 101 (4), 213-215 (2016).</li>
<li>Ebrahimi, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+vitro+evaluation+of+CRISPR+PX-LmGP63+vector+effect+on+pathogenicity+of+Leishmania+major+as+a+primary+step+to+control+leishmaniasis%5BTitle%5D)+AND+%22Microb+Pathog%22%5BJournal%5D)">In vitro evaluation of CRISPR PX-LmGP63 vector effect on pathogenicity of Leishmania major as a primary step to control leishmaniasis.</a> Microb Pathog. 161 (Pt A), 105281(2021).</li>
<li>Ebrahimi, S., Alipour, H., Azizi, K., Kalantari, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Construction+of+px-lmgp63+using+crispr-cas9+as+primary+goal+for+gp63+gene+knockout+in+Leishmania+major+and+leishmanization%5BTitle%5D)+AND+%22Jundishapur+J+Microbiol%22%5BJournal%5D)">Construction of px-lmgp63 using crispr-cas9 as primary goal for gp63 gene knockout in Leishmania major and leishmanization.</a> Jundishapur J Microbiol. 14 (1), 112965(2021).</li>
<li>Lim, J. M., Kim, H. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Basic+principles+and+clinical+applications+of+CRISPR-based+genome+editing%5BTitle%5D)+AND+%22Yonsei+Med+J%22%5BJournal%5D)">Basic principles and clinical applications of CRISPR-based genome editing.</a> Yonsei Med J. 63 (2), 105-113 (2022).</li>
<li>Han, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR-Cas9+delivery+to+hard-to-transfect+cells+via+membrane+deformation%5BTitle%5D)+AND+%22Sci+Adv%22%5BJournal%5D)">CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation.</a> Sci Adv. 1 (7), 1500454(2015).</li>
<li>Sano, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lentiviral+CRISPR%2FCas9-mediated+genome+editing+for+the+study+of+hematopoietic+cells+in+disease+models%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">Lentiviral CRISPR/Cas9-mediated genome editing for the study of hematopoietic cells in disease models.</a> J Vis Exp. (152), e59977(2019).</li>
<li>Tan, E., Chin, C. S. H., Lim, Z. F. S., Ng, S. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((HEK293+cell+line+as+a+platform+to+produce+recombinant+proteins+and+viral+vectors%5BTitle%5D)+AND+%22Front+Bioeng+Biotechnol%22%5BJournal%5D)">HEK293 cell line as a platform to produce recombinant proteins and viral vectors.</a> Front Bioeng Biotechnol. 9, 796991(2021).</li>
<li>Mccaig, W. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hyperglycemia+potentiates+a+shift+from+apoptosis+to+RIP1-dependent+necroptosis%5BTitle%5D)+AND+%22Cell+Death+Dis%22%5BJournal%5D)">Hyperglycemia potentiates a shift from apoptosis to RIP1-dependent necroptosis.</a> Cell Death Dis. , 1-14 (2018).</li>
<li>Deragon, M. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mitochondrial+ROS+prime+the+hyperglycemic+shift+from+apoptosis+to+necroptosis%5BTitle%5D)+AND+%22Cell+Death+Dis%22%5BJournal%5D)">Mitochondrial ROS prime the hyperglycemic shift from apoptosis to necroptosis.</a> Cell Death Dis. 6 (1), (2020).</li>
<li>Deragon, M. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mitochondrial+trafficking+of+MLKL%2C+Bak%2FBax%2C+and+Drp1+Is+mediated+by+RIP1+and+ROS+which+leads+to+decreased+mitochondrial+membrane+integrity+during+the+hyperglycemic+shift+to+necroptosis%5BTitle%5D)+AND+%22Int+J+Mol+Sci%22%5BJournal%5D)">Mitochondrial trafficking of MLKL, Bak/Bax, and Drp1 Is mediated by RIP1 and ROS which leads to decreased mitochondrial membrane integrity during the hyperglycemic shift to necroptosis.</a> Int J Mol Sci. 24 (10), 8609(2023).</li>
<li>LaRocca, T. J., Sosunov, S. A., Shakerley, N. L., Ten, V. S., Ratner, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hyperglycemic+conditions+prime+cells+for+RIP1-dependent+necroptosis%5BTitle%5D)+AND+%22J+Biol+Chem%22%5BJournal%5D)">Hyperglycemic conditions prime cells for RIP1-dependent necroptosis.</a> J Biol Chem. 291 (26), 13753-13761 (2016).</li>
<li>Pasparakis, M., Vandenabeele, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Necroptosis+and+its+role+in+inflammation%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Necroptosis and its role in inflammation.</a> Nature. 517 (7534), 311-320 (2015).</li>
<li>Yang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+Cytosolic+ATM%2FNEMO%2FRIP1+complex+recruits+TAK1+To+mediate+the+NF-%CE%BAB+and+p38+Mitogen-Activated+Protein+Kinase+%28MAPK%29%2FMAPK-activated+protein+2+responses+to+DNA+damage%5BTitle%5D)+AND+%22Mol+Cell+Biol%22%5BJournal%5D)">A Cytosolic ATM/NEMO/RIP1 complex recruits TAK1 To mediate the NF-κB and p38 Mitogen-Activated Protein Kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage.</a> Mol Cell Biol. 31 (14), 2774-2786 (2011).</li>
<li>Eng, V. V., Wemyss, M. A., Pearson, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+diverse+roles+of+RIP+kinases+in+host-pathogen+interactions%5BTitle%5D)+AND+%22Semin+Cell+Dev+Biol%22%5BJournal%5D)">The diverse roles of RIP kinases in host-pathogen interactions.</a> Semin Cell Dev Biol. 109, 125-143 (2021).</li>
<li>Liu, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((RIPK1+in+the+inflammatory+response+and+sepsis%3A+Recent+advances%2C+drug+discovery+and+beyond%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">RIPK1 in the inflammatory response and sepsis: Recent advances, drug discovery and beyond.</a> Front Immunol. 14, 1114103(2023).</li>
<li>Kowolik, C. M., Yee, J. -K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Preferential+transduction+of+human+hepatocytes+with+lentiviral+vectors+pseudotyped+by+Sendai+virus+F+protein%5BTitle%5D)+AND+%22Mol+Ther%22%5BJournal%5D)">Preferential transduction of human hepatocytes with lentiviral vectors pseudotyped by Sendai virus F protein.</a> Mol Ther. 5 (6), 762-769 (2002).</li>
<li>Chong, Z. X., Yeap, S. K., Ho, W. Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Transfection+types%2C+methods+and+strategies%3A+A+technical+review%5BTitle%5D)+AND+%22PeerJ%22%5BJournal%5D)">Transfection types, methods and strategies: A technical review.</a> PeerJ. 9, 11165(2021).</li>
<li>Keller, A. A., Maeß, M. B., Schnoor, M., Scheiding, B., Lorkowski, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Transfecting+Macrophages%5BTitle%5D)+AND+%22Methods+Mol+Biol+%28Clifton%2C+N.J%29%22%5BJournal%5D)">Transfecting Macrophages.</a> Methods Mol Biol (Clifton, N.J). 1784, 187-195 (2018).</li>
<li>Chanput, W., Peters, V., Wichers, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((THP-1+and+U937+cells.+The+impact+of+food+bioactives+on+health%3A+In+vitro+and+ex+vivo%5BTitle%5D)+AND+%22models%22%5BJournal%5D)">THP-1 and U937 cells. The impact of food bioactives on health: In vitro and ex vivo.</a> models. 159 (147), (2015).</li>
<li>Kutner, R. H., Zhang, X. Y., Reiser, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Production%2C+concentration+and+titration+of+pseudotyped+HIV-1-based+lentiviral+vectors%5BTitle%5D)+AND+%22Nat+Protoc%22%5BJournal%5D)">Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors.</a> Nat Protoc. 4 (4), 495-505 (2009).</li>
<li>Ricks, D. M., Kutner, R., Zhang, X. Y., Welsh, D. A., Reiser, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Optimized+lentiviral+transduction+of+mouse+bone+marrow-derived+mesenchymal+stem+cells%5BTitle%5D)+AND+%22Stem+Cells+Dev%22%5BJournal%5D)">Optimized lentiviral transduction of mouse bone marrow-derived mesenchymal stem cells.</a> Stem Cells Dev. 17 (3), 441-450 (2008).</li>
<li>Swainson, L., Mongellaz, C., Adjali, O., Vicente, R., Taylor, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lentiviral+transduction+of+immune+cells%5BTitle%5D)+AND+%22Methods+Mol+Biol+%28Clifton%2C+N.J.%29%22%5BJournal%5D)">Lentiviral transduction of immune cells.</a> Methods Mol Biol (Clifton, N.J.). 415, 301-320 (2008).</li>
</ol>

This protocol aims to provide detailed instruction and analysis of potential pitfalls in the efficiency and reliability of lentiviral transfection and transduction to create an RIP1 knockout U937 cell line. Although this method of transfection and transduction is labor and time-intensive, it is generally considered to be an efficient way to incorporate the chosen gRNA and Cas9 endonuclease into hard-to-transfect cell lines8,9,<sup class="xref"...

The use of the CRISPR/Cas9 gene-editing technology has been rapidly evolving since its discovery1,2,3. The ability to knock-in or knockout genes within cell lines or bacteria is invaluable to forwarding research and the understanding of intracellular mechanisms1,2,3,4,5,6. The CRISPR-Cas9 system improves upon previous gene editing methods, such as transcription activator-like effector nuclease (TALEN), by simplifying the engineering of gene specificity. This procedure includes two fundamental components: guide RNA (gRNA) used to locate the intended gene target, and Cas9, which is an endonuclease that modifies the intended genome location with a double-stranded DNA break3,4. The gRNA will act as a guide for the Cas9 endonuclease to locate and initiate the double-stranded break at the intended genetic sequence through Watson-Crick base pairing. The full process of genome editing by the CRISPR/Cas9 system involves cellular machinery repairing these double-stranded breaks in DNA through non-homologous end joining (NHEJ) or homologous recombination3,7. It is more likely that NHEJ will occur, effectively creating a mutation in the genome that results in a loss of expression for the target gene3,4.
Commercial sources have been able to create libraries of gRNA targets that can be expressed through bacterial growth and isolation, which significantly improves their ease of use. However, the main limitation of the CRISPR/Cas9 system is the difficulty in delivering the gRNA and Cas9 complex into target cell lines. These limitations arise in suspension cell lines, as they are generally referred to as hard-to-transfect8. Typical transfection methods are not generally efficient in delivering the CRISPR/Cas9 system into suspension cells, which is why viral delivery methods like lentiviral transfection and transduction are better suited for this type of cell line8,9.
This type of transfection requires a lentiviral vector that encodes the gRNA and Cas9 endonuclease along with added lentiviral packaging plasmids, which are transfected into a cell line that is capable of manufacturing lentiviral particles. A typically chosen cell line for this process is HEK293T cells, as they are easier to transfect and work very efficiently in the assembly of gRNA and Cas99,10. These particles are then released as lentiviruses into the supernatant, which can be used to transduce the gRNA and Cas9 into the intended suspension cell line, such as U937 human monocytes. As such, the procedure described here has the following changes compared to established methods: (1) Alternate transfection method for hard-to-transfect cell lines; (2) No need to concentrate CRISPR plasmid DNA or use ultracentrifuge; and (3) It eliminates the need for single-cell cloning.
The direct focus of this article was to knockout the RIP1 gene in U937 human monocytes. The canonical form of the highly inflammatory cell death pathway necroptosis is controlled by RIP1, which serves as a pivotal target for cell death studies.11,12,13,14 As RIP1 becomes active through autophosphorylation, it then recruits and causes direct phosphorylation and activation of receptor-interacting serine/threonine-protein kinase 3 (RIPK3/RIP3) and mixed lineage kinase domain-like (MLKL) pseudokinase to form the necrosome. Following this formation, the necrosome is free to move throughout the cell to interact with organelles such as the mitochondria12,13. At the mitochondria, RIP1 potentiates a positive feedback loop with cellular metabolism, directly impacting the production of mitochondrial ROS, which in turn promotes further autophosphorylation of RIP1, necrosome formation, and the downstream execution of necroptosis11,12,13,14.
While the focus of the current research group is the role of RIP1 in cell death, other reasons to study RIP1 include its roles in inflammation and infection. Upon activation by death receptors such as TNF receptors, RIP1 promotes the activation of the NF-&#954;B signaling pathway, which triggers the transcription of pro-inflammatory cytokines, chemokines, and other molecules essential for immune cell recruitment and the amplification of the inflammatory response15. In addition to NF-&#954;B activation, RIPK1 can also engage MAPK signaling pathways, further enhancing inflammation15,16. Regarding its role in responses to infection, RIP1 acts as a pivotal mediator of the host inflammatory response, particularly in response to pathogen-associated molecular patterns (PAMPs) recognized by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs)17. Moreover, during sepsis, RIP1 is activated by signaling through death receptors such as the TNF receptor, leading to the initiation of pro-inflammatory cascades. RIPK1 mediates the activation of the NF-&#954;B and MAPK pathways, promoting the production of pro-inflammatory cytokines such as TNF-&#945;, IL-1&#946;, and IL-6, which are key drivers of the systemic inflammatory response characteristic of sepsis18.

<table><tbody><tr><td>Adjusted DMEM Medium</td><td>Gibco</td><td>11995-040</td><td></td></tr><tr><td>Ampicillin</td><td>Sigma</td><td>A1593</td><td></td></tr><tr><td>bisBenzimide Hoechst 33342 trihydrochloride</td><td>Sigma</td><td>B2261</td><td></td></tr><tr><td>Complete RPMI-1640 Medium</td><td>Sigma</td><td>R6504</td><td></td></tr><tr><td>CRISPR NTC gRNA E.coli Strain</td><td>transOMIC</td><td>TELA1011</td><td></td></tr><tr><td>CRISPR RIP1 gRNA E.coli Strain</td><td>transOMIC</td><td>TEVH-1162203</td><td></td></tr><tr><td>End-over-end Rotator</td><td>Thermo Scientific</td><td></td><td></td></tr><tr><td>EVOS FL Fluorescence Microscope</td><td>Life Technologies</td><td></td><td></td></tr><tr><td>GenElute Plasmid Maxiprep Kit</td><td>Sigma</td><td>PLX15</td><td></td></tr><tr><td>Goat Anti-Rabbit IgG Antibody, (H+L) HRP conjugate</td><td>Sigma</td><td>AP307P</td><td></td></tr><tr><td>HEK293T Cells</td><td>ATCC</td><td></td><td></td></tr><tr><td>Incubator Shaker</td><td>New Brunswick Scientific</td><td></td><td></td></tr><tr><td>LB Agar</td><td>BD</td><td>244520</td><td></td></tr><tr><td>LB Broth</td><td>BD</td><td>244610</td><td></td></tr><tr><td>LV-MAX Lentiviral Packaging Mix</td><td>Gibco</td><td>A43237</td><td></td></tr><tr><td>MitoSOX Red</td><td>MedChemExpress</td><td>HY-D1055</td><td></td></tr><tr><td>NanoDrop Spectrophotometer</td><td>Thermo Scientific</td><td></td><td></td></tr><tr><td>Necrostatin-1</td><td>MedChemExpress</td><td>HY-14622A</td><td></td></tr><tr><td>OPTI-MEM</td><td>Gibco</td><td>31985-062</td><td></td></tr><tr><td>Puromycin</td><td>Sigma</td><td>P7255</td><td></td></tr><tr><td>Rabbit anti-human RIP1 mAb</td><td>Cell Signaling Technology</td><td>3493</td><td></td></tr><tr><td>SDS-PAGE and western blot equipment</td><td>BioRad</td><td></td><td></td></tr><tr><td>TNF-&amp;alpha;</td><td>MedChemExpress</td><td>HY-P7058</td><td></td></tr><tr><td>U937 Human Monocytes</td><td>ATCC</td><td></td><td></td></tr><tr><td>WST-1 Cell Proliferation Assay System</td><td>TaKaRa</td><td>MK400</td><td></td></tr><tr><td>X-tremeGENE 9 DNA Transfection Reagent</td><td>Roche Diagnostics</td><td>6365779001</td><td></td></tr><tr><td>z-VAD-FMK</td><td>APExBIO</td><td>A1902</td><td></td></tr></tbody></table>

generation of a rip1 knockout u937 cell line using the crispr-cas9 system

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System

This protocol outlines a procedure for knocking out the RIP1 gene using CRISPR/Cas9 in the human monocyte U937 cell line. The method utilizes designated guide RNA plasmids and lentiviral packaging plasmids to achieve RIP1 gene knockout. The protocol addresses challenges and improvements to traditional CRISPR methods, enabling its replication for future cell death studies. The resulting mutant cells can be used to investigate mechanistic changes in cell death, where functional RIP1 proteins would otherwise play a role. Viability assays demonstrated a significant reduction in cell death in knockout cells following necroptosis induction. Fluorescence microscopy revealed a marked decrease in mitochondrial reactive oxygen species (ROS) in knockout cells under the same conditions. Together, these functional assays confirm the loss of RIP1 protein. Optimized for use with U937 human monocytes, this procedure may also be adapted to target other key cell death regulators, yielding functional, non-lethal mutants. Potential pitfalls are addressed throughout to provide insights into challenges that may arise during mutant generation.

Following the production of a confluent population of RIP1 CRISPR mutant U937 cells, SDS-PAGE and Western blot analysis were performed. The Western blot analysis was used to determine the successful creation of a RIP1 CRISPR mutant cell line by assessing the loss of RIP1 protein expression levels. This determination was made based on the comparative result of WT U937 monocytes and NTC cells. In Figure 2, the expression of RIP1 was not detected for the 5 µg/mL puromycin ...

As CRISPR-related protocols become increasingly useful and accessible, complications and obstacles can still arise under specific experimental conditions. This protocol outlines the creation of a receptor-interacting serine/threonine-protein kinase 1 (RIPK1/RIP1) knockout human cell line using CRISPR/Cas9 and highlights potential challenges encountered during this process.

This protocol outlines a procedure for knocking out the RIP1 gene using CRISPR/Cas9 in the human monocyte U937 cell line. The method utilizes designated ...

generation-rip1-knockout-u937-cell-line-using-crispr-cas9

Research

JoVE Journal

Biology

Source: Vijayraghavan, S., Kantor, B. A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells. J. Vis. Exp. (2017).This video demonstrates the procedure for generating recombinant viral particles by transfecting embryonic kidney cells with plasmids encoding viral proteins and a gene of interest.

Generation of Recombinant Viral Particles Using Embryonic Kidney Cells

CRISPR/Cas9 is a robust system to produce disruption of genes and genetic elements. Here we describe a protocol for the efficient creation of genomic deletions in mammalian cell lines using CRISPR/Cas9.

Generation of Genomic Deletions in Mammalian Cell Lines via CRISPR/Cas9

Genome editing tools such as the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas (CRISPR-associated) system have greatly improved gene targeting efficiency in human induced pluripotent stem cells (hiPSCs). This manuscript describes a protocol for generating lineage specific hiPSC reporter using CRISPR/Cas system assisted homologous recombination.

Efficient Generation of hiPSC Neural Lineage Specific Knockin Reporters Using the CRISPR/Cas9 and Cas9 Double Nickase System

Recent advances in the ability to genetically manipulate somatic cell lines hold great potential for basic and applied research. Here, we present two approaches for CRISPR/Cas9 generated knockout production and screening in mammalian cell lines, with and without the use of selectable markers.

Selection-dependent and Independent Generation of CRISPR/Cas9-mediated Gene Knockouts in Mammalian Cells

A protocol for fast CRISPR/Cas9-mediated gene disruption in mouse and human primary hematopoietic cells is described in this article. Cas9-sgRNA ribonucleoproteins are introduced via electroporation with sgRNAs generated through in vitro transcription and commercial Cas9. High editing efficiencies are achieved with limited time and financial cost.

Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9

Here, we present a protocol to genetically modify primary or expanded human natural killer (NK) cells using Cas9 Ribonucleoproteins (Cas9/RNPs). By using this protocol, we generated human NK cells deficient for transforming growth factor–b receptor 2 (TGFBR2) and hypoxanthine phosphoribosyltransferase 1 (HPRT1).

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins

This protocol provides a method to facilitate the generation of defined heterozygous or homozygous nucleotide changes using CRISPR-CAS9 in human pluripotent stem cells.

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

In this protocol, we describe the technical procedures to generate brown adipose tissue (BAT)-specific knockout mice leveraging a combined Cre-LoxP, CRISPR-Cas9, and adeno-associated virus (AAV) single-guide RNA (sgRNA) system. The described steps include the design of the sgRNAs, the preparation of the AAV-sgRNA particles, and the microinjection of AAV into the BAT lobes.

Generation of Brown Fat-Specific Knockout Mice Using a Combined Cre-LoxP, CRISPR-Cas9, and Adeno-Associated Virus Single-Guide RNA System

This article reports the construction of centromere-associated protein-E (CENP-E) knockout cells using the CRISPR/Cas9 system and three phenotype-based screening strategies. We have utilized the CENP-E knockout cell line to establish a novel approach to validate the specificity and toxicity of the CENP-E inhibitors, which is useful for drug development and biological research.

Generation of Centromere-Associated Protein-E CENP-E-/- Knockout Cell Lines using the CRISPR/Cas9 System

The THP-1 cell line is widely used as a model to investigate the functions of human monocytes/macrophages across various biology-related research areas. This article describes a protocol for efficient CRISPR-Cas9-based engineering and single-cell clone isolation, enabling the production of robust and reproducible phenotypic data.

Electroporation-Based CRISPR-Cas9-Mediated Gene Knockout in THP-1 Cells and Single-Cell Clone Isolation

Here, we describe a protocol for generating maternal mutant that couples a stable zpc:cas9 knock-in line with Tol2-mediated delivery of sgRNA expression cassettes.

Generation of Maternal Mutants Using zpc:cas9 Knock-in Zebrafish

Learn CRISPR-Cas9 gene editing to generate a RIP1 knockout U937 cell line for studying receptor-interacting protein kinase 1 function. This protocol demonstrates precise genetic modification techniques.

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System

Explore More Videos